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Highlights
•Details of a convenient, laboratory-scale synthesis of M372049 are disclosed.
•A chiral gamma lactam was prepared and characterized by X-ray crystallography.
•Solid-phase peptide synthesis was utilized without special equipment.

Abstract
The Natriuretic Peptide Receptors (NPRs) regulate vascular sodium levels and have been of significant
interest for the potential treatment of hypertension and related cardiovascular complications. The
peptidomimetic antagonist M372049 is a valuable probe for the study of NPR-C signaling,
unfortunately it is presently not commercially available. Described is a detailed protocol for its
synthesis that does not require specialized apparatus and builds upon a prior patent from Veale and
colleagues. Key steps include a base-mediated lactam formation and a solid-supported peptide
synthetic sequence. An X-ray crystal structure of a key lactam intermediate was obtained to confirm
the structure and relative stereochemistry of the compound.
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Abbreviations
Boc tert-butoxycarbonyl
DCE 1,2-dichloroethane
DCM dichloromethane
DMF N,N-dimethylformamide
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EDT 1,2-ethanedithiol
Fmoc fluorenylmethyloxycarbonyl
HATU hexafluorophosphate azabenzotriazole tetramethyl uronium
HOBt 1-hydroxybenzotriazole
LC-MS liquid chromatography-mass spectrometry
PDA photodiode array
SPPS solid phase peptide synthesis
TFA trifluoroacetic acid
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Introduction
Natriuretic peptides (NPs) are hormones secreted in the cardiac atria in response to cardiovascular
stress that bind and activate natriuretic peptide receptors (NPRs), leading to the excretion of sodium,
vasodilation, and a decrease in blood pressure, among several effects [1]. One subtype of this receptor,
NPR-C, is highly expressed in atrial myocardium and acts in part as a clearance receptor to decrease
circulating levels of NPs, though it also transduces signals to the G protein Gi and decreases cAMP
production. Most recently, NPR-C has also been implicated in persistent hypertension after repair of
congenital aortic coarctation [2]. Truncated NPs have been investigated and are potent agonists of
NPRs [3], [4], but presumably their plasma instability, rapid clearance, and/or lack of bioavailability have
thus far precluded practical use. A possible alternative approach to the treatment of hypertension and
other related cardiovascular disorders would be to inhibit NPR-C and increase the concentration of
circulating NPs. This approach was reported by investigators at AstraZeneca [5], and the
peptidomimetic M372049 (1) is presently considered to be the best-in-class NPR-C antagonist.
However, its lack of commercial availability has precluded its use as a tool compound to support in
vivo cardiovascular studies. Herein is described a detailed protocol for the preparation of this
important compound [6], using the patent including M372049 from Veale and colleagues as a starting
point [7].
We considered several syntheses of M372049, but the one which we ultimately pursued deviates only
slightly from the patent, with the retrosynthesis outlined in Fig. 1. The molecule can be assembled via
Fmoc-based solid phase peptide synthesis (SPPS) [8], with the key building blocks 2 and 3 prepared
separately to increase the convergency of the synthesis. Given the valuable nature of lactam 3, we
ultimately explored using lower amounts of this building block in the SPPS to increase the efficiency.

Fig. 1. Retrosynthesis of M372049 (1).

Results
We began by coupling quinoxaline-2-carboxylic acid 5 to aniline 6 to furnish amide 7 in high yield,
followed by hydrolysis to give the desired acid 2 (Scheme 1). These were of acceptable purity to push
forward without the need for further purification beyond the aqueous workup.

Scheme 1. Synthesis of western quinoxaline-amide-acid 2.
The most challenging step in generating 1 was the efficient preparation of sufficient quantities of γlactam 3 for the SPPS portion of the synthesis (Scheme 2). This is an example of a “Freidinger lactam”,
which is a useful moiety for peptide conformational restriction [9], [10], [11]. The synthesis began with the
amide coupling of N-Boc D-methionine (8) to isoleucine methyl ester (9), which generated dipeptide 10.
Formation of the lactam ring was facilitated by treatment of 10 with Meerwein’s reagent to form a
trialkylsulfonium leaving group, with the intermediate sufficiently stable for identification and
monitoring by LC–MS. Addition of K2CO3 and heating for 12 h gave lactam 11. IR analysis showed a shift
in the amide carbonyl stretch from 1649 cm−1 in 10 to 1695 cm−1 in 11, consistent with the conversion
of a secondary amide to a γ-lactam, rather than a lactone. To confirm formation of the lactam and its
stereochemical configurations, an X-ray crystal structure of 12 was obtained (Fig. 2, CCDC Deposition
Number 1973363).

Scheme 2. Synthesis of γ-lactam 3.

Fig. 2. X-ray structure of lactam 12.
During the hydrolysis to give acid 12, Veale and colleagues reported partial epimerization after the
workup [7], which required a separate crystallization to obtain diastereomerically pure material. In our

protocol, dilution of the crude reaction mixture with H2O and acidification with aqueous HCl led to
precipitation of a white solid which was filtered off to cleanly give the desired product as a single
diastereomer. Lastly, removal of the Boc group with TFA followed by treatment with FmocCl gave the
Fmoc-protected γ-lactam to be used in the SPPS portion of the synthesis. All intermediates in the
synthesis of 3 were able to be isolated in solid form, in high purity, without recourse to column
chromatography.
SPPS was performed with a Rink amide resin according to common protocols (Scheme 3) [8], using
Kaiser tests to qualitatively confirm the completion of all coupling and deprotection steps
(see Supporting Info for details). Reactions were performed in glass vials without stirring, to avoid
breaking down the resin to particles too small to filter, though a shaker could optionally be used. Initial
attempts to couple standard peptides at room temperature were sluggish and did not go to completion
without the use of large excesses of peptides. We found that using 3 equivalents of peptide and
heating at 45 °C in minimal solvent for 3–12 h led to complete coupling. To prevent potential
aspartamide formation during deprotection after the coupling of protected aspartic acid, the
deprotection cocktail was switched from 20% piperidine in DMF to 5% piperazine in 0.1 M HOBt in 9:1
NMP:EtOH [12]. Given the valuable nature of lactam 3, we explored lower substrate loadings for this
step. We found that the use of 1.3 equivalents of 3 and heating at 45 °C gave a complete reaction
within 12 h. The final coupling of quinoxaline-acid 2 was run under our standard peptide coupling
conditions, given the ease at which gram quantities of this compound could be produced. After
treatment of the resin with a TFA-based deprotection cocktail at room temperature for 4 h, 1.2 g of
crude material was obtained (1.7 g theoretical yield). Resubjection of the resin to the deprotection
cocktail at 60 °C for 12 h did not yield a further significant quantity of crude material (47 additional
milligrams obtained). The crude final product 1 was purified using automated flash chromatography on
a 30 g C18 column and eluted with a 0.1% TFA in acetonitrile–water gradient. Pooling of fractions
which contained the desired product gave 215 mg of material with minor impurities which could not
be separated via flash chromatography. Fortunately, these impurities could be removed by trituration
with 9:1 ether:chloroform. The synthesis yielded 195 mg of desired product (11% overall yield) at >99%
purity without the need for preparative HPLC purification. 19F NMR with 1,4-difluorobenzene as
internal standard confirmed that 1 was isolated as the mono-TFA salt.

Scheme 3. Assembly of M372049 via SPPS.

Conclusion
Alternatively, the three C-terminal residues of the peptidomimetic could be connected by solution
phase, then joined to the preformed western half of M372049 containing the γ-lactam. Since the Cterminal tripeptide was synthesized rapidly on solid support without recourse to chromatography, and
since the on-resin synthesis did not require stirring or special apparatus, it is highly scalable, and a fully
solution phase synthesis would seem to offer no obvious advantages. In conclusion, an efficient,
scalable protocol for the synthesis of the NPR-C antagonist M372049 is disclosed.
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